Silexion Files Adjusted Financials Post-Reverse Split; Cash Down to $2.4M, Going Concern Warning
SLXN is trading near its 52-week low of $0.411 (9.2% above the low).
Summary
Silexion Therapeutics filed adjusted financial statements after its reverse split, revealing cash dropped to $2.4 million and a going concern warning with only several months of runway.
Key Events · Financing and Capital Events · SLXN
-
Adjusted Financials Filed
Silexion filed retroactively adjusted audited financial statements for the year ended December 31, 2025 and unaudited interim financial statements for the quarter ended March 31, 2026, reflecting the 1-for-10 reverse share split effective May 29, 2026.
-
Cash Position Deteriorates
Cash and cash equivalents declined from $5,991 thousand at December 31, 2025 to $2,413 thousand at March 31, 2026, a decrease of $3,578 thousand.
-
Going Concern Warning
Management concluded there is substantial doubt about the company's ability to continue as a going concern, with current funds sufficient for only several months from the date the financial statements are issued.
-
Subsequent Financing Events
In May 2026, a warrant exercise inducement transaction raised approximately $1.0 million; ATM sales in April and May 2026 raised $1,085 thousand; and $404 thousand of Related Party Promissory Note was converted into ordinary shares.
Analysis · SLXN · Life Sciences
Silexion Therapeutics filed its retroactively adjusted financial statements following the 1-for-10 reverse stock split. The updated numbers show cash and cash equivalents fell from $6.0 million at year-end 2025 to $2.4 million at March 31, 2026, and management reiterates substantial doubt about the company's ability to continue as a going concern, with funds sufficient for only several months. The filing also discloses subsequent events including a May 2026 warrant inducement transaction that raised about $1.0 million and ATM sales in April and May 2026 that raised $1.1 million. The going concern warning and declining cash position are critical for investors.
At the time of this filing, SLXN was trading at $0.45 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $489K. The 52-week trading range was $0.41 to $80.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.